Cure8 research brief
If validated, fecal neuraminidase activity could become a functional biomarker reflecting early host–microbe changes before Crohn’s disease onset, which might help identify higher-risk individuals for closer monitoring or research enrollment.
Researchers, clinicians, and patients/families interested in early biomarkers and microbiome-related mechanisms in Crohn’s disease.
This study measured fecal neuraminidase activity in people who later developed Crohn’s disease (CD) versus matched healthy first-degree relatives using samples from the prospective GEM cohort.
Higher fecal neuraminidase activity was associated with increased odds of future CD diagnosis and correlated with inflammatory proteins, fecal calprotectin, and specific gut microbial taxa.
The authors used a fluorometric assay for neuraminidase activity, protein profiling (OLINK) for serum inflammatory signatures, fecal calprotectin as an inflammation marker, and 16S rRNA sequencing for microbial composition.
Adjusting for fecal calprotectin reduced the association between neuraminidase activity and future CD, suggesting linked inflammatory processes. This work positions fecal neuraminidase activity as a potential functional biomarker reflecting host–microbe interactions in the preclinical phase of CD, but it does not establish causation or clinical utility yet.
Findings are associative from the GEM cohort and reported at abstract/summary depth; further validation and evaluation of clinical predictive value are needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
